

## Biomarkers in Heart Failure

Pedro Pimenta de Mello Spineti<sup>ID</sup>

Hospital Universitário Pedro Ernesto, Rio de Janeiro, RJ – Brazil

Hospital Unimed-Rio, Rio de Janeiro, RJ – Brazil

Short Editorial related to the article: High Level of Lipoprotein(a) as Predictor for Recurrent Heart Failure in Patients with Chronic Heart Failure: a Cohort Study

The World Health Organization defines biomarker as any substance, structure, or process that can be measured in the body or its products and influences or predicts the incidence or outcome of a disease.<sup>1</sup> Biomarkers can serve multiple purposes: diagnostic, disease staging, prognostic and prediction and monitoring of responses to an intervention.<sup>1</sup>

A useful biomarker should allow repeated and accurate measurements with a rapid turnaround time at a reasonable cost, should provide information that is not already available from careful clinical assessment and its performance should be superior to other available tests, and should assist decision making and enhance clinical care.<sup>2</sup>

Several biomarkers have been studied in the context of acute and chronic heart failure (HF). In 2016 the American Heart Association issued a statement on the Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure.<sup>3</sup> After an extensive review, they stated that a number of biomarkers associated with HF are well recognized, and measuring their concentrations in circulation can be a convenient and noninvasive approach to provide important information about disease severity and help in the detection, diagnosis, prognosis, and management of HF. These include natriuretic peptides, soluble suppressor of tumorigenicity 2 (ST-2), highly sensitive troponin, galectin-3,

mid regional pro adrenomedullin (MR-proADM), cystatin-C, interleukin-6 and procalcitonin. There is a need to further evaluate existing and novel markers for guiding therapy.

The 2018 Brazilian Guidelines on Chronic and Acute Heart Failure recommends the use of natriuretic peptides with diagnostic and prognostic purposes.<sup>3</sup> According to these guidelines other biomarkers such as troponins T and I, galectin-3 and ST-2 may add prognostic information in HF patients.<sup>4</sup>

More recently Swedish investigators reported that elevated plasma levels of NT-proBNP, MR-proADM, copeptin, and cystatin C were associated with higher mortality after discharge in a cohort of 286 patients hospitalized for newly diagnosed or exacerbated HF.<sup>5</sup> Nonetheless, NT-proBNP was the only biomarker to predict the risk of re-hospitalization due to cardiac causes.

Lipoprotein(a) (Lp(a)) is a biomarker associated with increased risk of atherosclerotic disease. In 2016 Kamstrup and Nordestgaard demonstrated a clear stepwise association of elevated Lp(a) levels with increased risk of HF in a study with more than 98,000 danish participants.<sup>5</sup> In addition, they provided genetic evidence that this association was mediated at least partly via coronary heart disease (CAD) and aortic valve stenosis.

This issue of *Arquivos Brasileiros de Cardiologia* presents the paper of Jianlong et al.<sup>6</sup> examining the prognostic value of Lp(a) in Chinese patients admitted for decompensated HF of ischemic origin. An Lp(a) greater than 20,6 mg/dL was associated with 3 fold increase in readmission for HF. Patients with higher Lp(a) levels also had higher NT-proBNP levels, higher NYHA class, lower left ventricle ejection fraction, more CAD. The results were adjusted for these covariates with a slight decrease in the hazard ratio.

Lp(a) may be a prominent new biomarker in patients with HF of ischemic origin. More studies in different populations are needed to validate these results.

### Keywords

Biomarkers; Lipoproteins; Heart Failure; Hypertension; Diabetes Mellitus.

**Mailing Address: Pedro Pimenta de Mello Spineti** •  
Boulevard 28 de setembro, 77. Postal Code 20551-030, Vila Isabel, RJ – Brazil  
E-mail: pedrospineti@yahoo.com.br

**DOI:** 10.5935/abc.20190167

---

## References

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther.* 2001;69(3):89–95.
2. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. *Circulation.* 2007;115(8):949–952.
3. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. *Circulation.* 2017; 135(22):e1054-e1091.
4. Comitê Coordenador da Diretriz de Insuficiência Cardíaca. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Sociedade Brasileira de Cardiologia. *Arq Bras Cardiol.* 2018;111(3):436-539.
5. Molvin J, Jujic A, Bachus E, Gallo W, Tasevska-Dinevska G, Holm H, et al. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients. *ESC Heart Fail.* 2019 Jul 24. [Epub ahead of print]
6. Jianlong Y, Yanbin P, Junhui X, Wenxue M, Li L, Zhong M, et al. High level of lipoprotein(a) as predictor for recurrent heart failure in patients with chronic heart failure: a Cohort Study. *Arq Bras Cardiol.* 2019; 113(2):197-204.



This is an open-access article distributed under the terms of the Creative Commons Attribution License